ALBUQUERQUE, N.M. (KRQE) – A new treatment for a deadly immune disorder has been found by researchers at the UNM Comprehensive Cancer Center (UNMCCC).
Mastocytosis, a rare and sometimes deadly immune disorder, is now being treated by a drug called Midostaurin. Midostaurin helps patients with advance Mastocytosis conditions. The most serious type is Leukemia where typically, patients live only about six months after their diagnosis.
Based on a recent clinical trial of Midostaurin, people with advanced Mastocytiosis have lived an average of 28 months longer.
Dr. Tracy George, a researcher at the UNMCCC, and the top American Pathology Expert in Mastocytosis Pathology, joined KRQE’s This Morning team to discuss the study and new drug. Watch above.
The research was recently published in The New England Journal of Medicine, one of the nation’s leading medical journals.
For more information, visit their website.